Citations 307

Unravelling hypothyroidism in AL amyloidosis: Authors' reply

Journal of Internal Medicine | September 1, 2017 | Volume: 283 | Issue: 1 | Pages: 108-108

10.1111/joim.12681 | PMID 28861923

Click here to view the Letter to the Editor by Dr. Benvenga and Guarneri
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation

British Journal of Haematology | July 12, 2017 | Volume: 178 | Issue: 6 | Pages: 888-895

10.1111/bjh.14830 | PMID 28699650

SummaryThe significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above the upper limit of normal (ULN) with disease characteristics and outcome. Four hundred and nine patients had an LDH above ULN, representing 40% of the study population. Patients with an elevated LDH were older, were less likely to be male and had more extensive organ involvement compared to patients with a normal LDH. Patients with high LDH had greater cardiac and renal dysfunction. Elevated LDH was an independent prognostic marker for overall survival and for death within 6 months of diagnosis, but this was restricted to patients not eligible for stem cell transplant. Serum LDH may act as a marker for organ damage and should be explored as a potential marker for tissue healing and organ recovery.
Clinical trials evaluating potential therapies for light chain (AL) amyloidosis

Expert Opinion on Orphan Drugs | June 10, 2017 | Volume: 5 | Issue: 8 | Pages: 655-663

10.1080/21678707.2017.1341834 | PMID 34567849

Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer

Leukemia & Lymphoma | June 8, 2017 | Volume: 59 | Issue: 2 | Pages: 288-299

10.1080/10428194.2017.1334124 | PMID 28592156

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Journal of Internal Medicine | April 25, 2017 | Volume: 281 | Issue: 6 | Pages: 611-619

10.1111/joim.12617 | PMID 28439924

AbstractBackgroundData on the effect of systemic immunoglobulin light chain amyloidosis (AL amyloidosis) on thyroid function are limited.ObjectiveTo assess the prevalence of hypothyroidism in AL amyloidosis patients and determine its predictors.Methods1142 newly diagnosed AL amyloidosis patients were grouped based on the thyroid‐stimulating hormone (TSH) measurement at diagnosis: hypothyroid group (TSH above upper normal reference; >5 mIU L−1; n = 217, 19% of study participants) and euthyroid group (n = 925, 81%). Predictors for hypothyroidism were assessed in a binary multivariate model. Survival between groups was compared using the log‐rank test and a multivariate analysis.ResultsPatients with hypothyroidism were older, more likely to present with renal and hepatic involvement and had a higher light chain burden compared to patients in the euthyroid group. Higher proteinuria in patients with renal involvement and lower albumin in patients with hepatic involvement were associated with hypothyroidism. In a binary logistic regression model, age ≥65 years, female sex, renal involvement, hepatic involvement, kappa light chain restriction and amiodarone use were independently associated with hypothyroidism. Ninety‐three per cent of patients in the hypothyroid group with free thyroxine measurement had normal values, consistent with subclinical hypothyroidism. Patients in the hypothyroid group had a shorter survival compared to patients in the euthyroid group (4‐year survival 36% vs 43%; P = 0.008), a difference that was maintained in a multivariate analysis.ConclusionA significant proportion of patients with AL amyloidosis present with hypothyroidism, predominantly subclinical, which carries a survival disadvantage. Routine assessment of TSH in these patients is warranted.
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 44-45

10.1080/13506129.2017.1281117 | PMID 28434304

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 40-41

10.1080/13506129.2016.1277696 | PMID 28434371

First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 42-43

10.1080/13506129.2016.1272454 | PMID 28434299

Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition

Annals of Medicine | March 8, 2017 | Volume: 49 | Issue: 7 | Pages: 545-551

10.1080/07853890.2017.1304649 | PMID 28271734

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

Blood | January 26, 2017 | Volume: 129 | Issue: 15 | Pages: 2111-2119

10.1182/blood-2016-11-751628 | PMID 28126928

Key Points Significant improvement in outcome is a reality for newly diagnosed AL amyloidosis in the past decade. Six-month mortality among transplant ineligible patients has declined since 2005.